(The Lion) With an emergency docket lawsuit before the Supreme Court of the United States over regulation of the chemical abortion pill, Food and Drug Administration Commissioner Marty Makary resigned Tuesday, and his replacement could aid or aggravate pro-life Americans.
President Donald Trump announced Makary’s resignation in a Truth Social post Tuesday, thanking him for his work and leadership. Makary did not specify a reason for his resignation, but multiple reports speculate it comes after disagreement with the administration over the approval of flavored vapes, according to Newsweek.
In the same post, Trump announced FDA Deputy Commissioner for Human Foods Kyle Diamantas will fill the role of acting commissioner until another appointee is confirmed.
Diamantas joined the FDA in February 2025 and has supervised food-safety policy in both the Human Foods Program and the Office of Inspections and Investigations, Newsweek reports. Unlike most previous FDA leaders, Diamantas does not hold a medical degree but previously worked as a corporate lawyer at Jones Day and Baker Donelson, according to Politico.
His legal background, however, is stirring some frustration and shock among pro-life Americans. Diamantas is listed as a junior associate representative for Planned Parenthood of Greater Orlando in a 2017 case.
Tweet This: Acting FDA Commissioner Kyle is listed as a junior associate representative for Planned Parenthood of Greater Orlando in a 2017 legal case.
[Click here to subscribe to Pregnancy Help News!]
Founder of Live Action Lila Rose critiqued the pro-abortion affiliation in a post on X, gaining the attention of many other pro-life leaders. Trump advisor Alex Bruesewitz defended Diamantas, calling him a “good man” and “pro-life” and said Diamantas removed himself from the 2017 case because of personal beliefs.
President of the March for Life Education and Defense Fund Jennie Bradley Lichter said Diamantas’ name on the 2017 case is “not a reason for concern about his approach in his new job,” adding that she is “optimistic” after a call with him Tuesday night.
“Within hours of being handed this big new job, he was on the phone with pro-life leaders – which is an encouraging sign of where his priorities lie,” she said in a post on X. “After talking w him I’m optimistic that the cause of Life will get a full and fair hearing at the FDA, incl real movement on the mifepristone safety study.”
Diamantas will fill the position until Trump appoints a new commissioner. President of Susan B. Anthony Pro-Life America Marjorie Dannenfelser called on the administration to fill the vacant position with a commissioner who will “end the mail-order abortion drug regime.”
“We must return immediately to the 1st Trump Administration standard of in-person dispensing to protect women from coercion and abuse and allow the enforcement of pro-life state laws,” she said in a post on X.
The state of Louisiana is currently suing the FDA for Biden-era rules that allow mifepristone, the chemical abortion pill, to be mailed into the state, where abortion is banned. The Fifth Circuit Court of Appeals temporarily reinstated the older rules, though the U.S. Supreme Court paused that order May 4 until further review. The Court may issue a ruling for the case on emergency docket Thursday when its temporary extension ends, according to The Guardian.
Editor's note: This article was published by The Lion and is reprinted with permission.
